Filana Therapeutics (FLNA) EV to FCF (2010 - 2026)

Filana Therapeutics has reported EV to FCF for 17 years, with the latest figure at 6.57 in Q2 2026.

• On a quarterly basis, EV to FCF rose 30.81% year-over-year to 6.57 in Q2 2026; TTM through Jun 2026 was 0.86, a 230.45% increase from a year earlier, with the FY2025 full-year figure at 0.0, down 103.55% from the prior year.
• EV to FCF was 6.57 for Q2 2026 at Filana Therapeutics, up from 0.55 in the prior quarter.
• The five-year high for EV to FCF was 6.57 in Q2 2026, with the low at 73.95 in Q2 2022.
• Average EV to FCF over 5 years is 28.91, with a median of 29.08 recorded in 2024.
• The sharpest annual moves came in 2024 and 2025: EV to FCF tumbled 217.31% in 2024, then surged 123.87% in 2025.
• Over 5 years, EV to FCF stood at 49.17 in 2022, then advanced by 24.53% to 37.11 in 2023, then soared by 100.65% to 0.24 in 2024, then sank by 105.93% to 0.01 in 2025, then surged by 45944.8% to 6.57 in 2026.
• The last three EV to FCF figures came in at 6.57 (Q2 2026), 0.55 (Q1 2026), and 0.01 (Q4 2025), per Business Quant data.